Get the Stockscreener App
0.1878
1.16%
-0.0022
After Hours:
.30
0.1122
+59.74%
Liminatus Pharma Inc stock is traded at $0.1878, with a volume of 496.78K.
It is down -1.16% in the last 24 hours and down -12.69% over the past month.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
See More
Previous Close:
$0.19
Open:
$0.1875
24h Volume:
496.78K
Relative Volume:
0.13
Market Cap:
$8.43M
Revenue:
-
Net Income/Loss:
$-9.88M
P/E Ratio:
-0.5154
EPS:
-0.3644
Net Cash Flow:
$-9.98M
1W Performance:
+1.51%
1M Performance:
-12.69%
6M Performance:
-82.11%
1Y Performance:
-97.02%
1-Day Range:
$0.185
$0.1902
1-Week Range:
$0.1763
$0.192
52-Week Range:
$0.1592
$33.66
Liminatus Pharma Inc Stock (LIMN) Company Profile
Name
Liminatus Pharma Inc
Sector
Industry
Phone
213-273-5453
Address
12611 HIDDENCREEK WAY, CERRITOS
Compare LIMN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LIMN
Liminatus Pharma Inc
|
0.1878 | 8.40M | 0 | -9.88M | -9.98M | -0.3644 |
VRTX
Vertex Pharmaceuticals Inc
|
430.44 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.76 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
804.25 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.48 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
308.74 | 30.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
Liminatus Pharma Inc Stock (LIMN) Latest News
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
LIMN Should I Buy - Intellectia AI
Liminatus Pharma 1Q 2026: Net loss $1.12M, Diluted EPS $(0.03) — 10-Q Summary - TradingView
Liminatus Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Liminatus Pharma (NASDAQ: LIMN) Q1 loss, going concern and Nasdaq listing risks - Stock Titan
TradingKey - TradingKey
Why Liminatus (LIMNW) is still under the radar (+33.11%) 2026-05-11Sector Leader - newser.com
The key risks discussed in Liminatus Pharma (LIMN) earnings | LIMN QX Earnings: Liminatus Pharma Reports No Revenue, Pipeline FocusHigh Attention Stocks - newser.com
LIMN QX Earnings: Liminatus Pharma Reports No Revenue, Pipeline FocusMacro Risk - newser.com
What Liminatus (LIMNW) disclosed about workforce costs | LIMNW: Liminatus Warrants Report No Earnings DataLiquidity Risk - newser.com
Net current asset value per share of Liminatus Pharma, Inc. – NASDAQ:LIMN - TradingView
LIMNW Price History for Liminatus Pharma Warrants Stock - Barchart.com
Liminatus Pharma Stock Surges to Record High After Regaining Nasdaq Compliance - MSN
Is Liminatus (LIMNW) stock trending down today | Liminatus Posts No Financials, Pipeline Drives Warrant MovesHigh Growth - newser.com
Is Liminatus Pharma (LIMN) stock worth buying today Earnings ReportPricing Power - Xã Châu Thành
LIMNW (Liminatus Pharma) Cyclically Adjusted Price-to-FCF : (As of Apr. 22, 2026) - GuruFocus
LIMNW (Liminatus Pharma) PB Ratio : (As of Apr. 21, 2026) - GuruFocus
LIMNW (Liminatus Pharma) Cyclically Adjusted PB Ratio : (As of Apr. 21, 2026) - GuruFocus
Is Liminatus Pharma (LIMN) stock forming lower lows (Institutional Selling) 2026-04-20Social Flow Trades - Cổng thông tin điện tử tỉnh Lào Cai
Liminatus Pharma (LIMN) Stock: Is It Overvalued vs Peers (Bearish Sentiment) 2026-04-18Reward Analysis - Xã Thanh Hà
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market SessionAcurx Pharmaceuticals (NASDAQ:ACXP), Ali - Benzinga
Quarterly Recap: What is the cash position of Liminatus Pharma Inc2026 Trade Ideas & Free Reliable Trade Execution Plans - baoquankhu1.vn
Earnings Report: Is Liminatus Pharma Inc Equity Warrant stock undervalued right nowTrade Volume Report & Verified Stock Trade Ideas - baoquankhu1.vn
Resistance Check: Can INNOVATE Corp stock outperform in a bear marketEarnings Growth Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
What is the sentiment around Liminatus Pharma (LIMN) Stock | Price at $0.18, Down 1.13%Hot Stocks - newser.com
Quarterly Earnings: Can NRDS be recession proofGlobal Markets & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Update Recap: Will SOBR outperform during market rallies2026 Performance Recap & Reliable Breakout Forecasts - baoquankhu1.vn
Breakout Move: Can Liminatus Pharma Inc Equity Warrant reach resistance levels soonFed Meeting & Weekly Top Performers Watchlists - baoquankhu1.vn
LIMN Rebounds Close to Support Level, Yet Downward Trend Remains Firm - Bitget
Is Liminatus Pharma (LIMN) Stock a Safe Investment | Price at $0.19, Up 6.29%Smart Money Flow - newser.com
Growth Value: Is Liminatus Pharma Inc forming a breakout pattern2026 Patterns & Entry Point Strategy Guides - baoquankhu1.vn
Retail Trends: Whats the fair value of Liminatus Pharma Inc Equity Warrant stock2026 Intraday Action & Weekly Sector Rotation Insights - baoquankhu1.vn
Liminatus Pharma 2025 Annual Report: Pre-Clinical Cancer Therapy Pipeline, Strategy, and Risk Overview - Minichart
Liminatus Pharma 2025 10-K — $0 Revenue, Net Loss $10.21M - TradingView — Track All Markets
Liminatus Pharma (NASDAQ: LIMN) faces cash strain, dilution and Nasdaq listing risks - Stock Titan
Liminatus Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Insider Trends: Is Liminatus Pharma Inc stock a smart retirement pick2026 PreEarnings & Weekly Return Optimization Plans - baoquankhu1.vn
FOMO Trade: Is Liminatus Pharma Inc a good ESG investment2026 Momentum & Capital Efficient Trading Techniques - baoquankhu1.vn
Institution Moves: Is Liminatus Pharma Inc stock a top performer YTD2026 Buyback Activity & Stepwise Trade Execution Plans - baoquankhu1.vn
Liminatus Pharma, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Jobs Data: What are the future prospects of Liminatus Pharma Inc Equity WarrantTrade Analysis Report & AI Driven Price Predictions - baoquankhu1.vn
Fundamentals Check: Is Liminatus Pharma Inc Equity Warrant subject to activist investor interest2026 Breakouts & Daily Profit Focused Stock Screening - baoquankhu1.vn
Moving Averages: What are Liminatus Pharma Incs recent SEC filings showingJobs Report & Verified Momentum Stock Alerts - baoquankhu1.vn
LIMN Stock Price, Quote & Chart | LIMINATUS PHARMA INC-CL A (NASDAQ:LIMN) - ChartMill
Weekly Earnings: Is Liminatus Pharma Inc Equity Warrant stock undervalued right nowMarket Activity Summary & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Aug Patterns: Can BPMC maintain its current growth rate2026 Fundamental Recap & Accurate Technical Buy Alerts - baoquankhu1.vn
Liminatus eyes clinic with CD47-blockade antibody IBA-101 - BioWorld MedTech
Liminatus Pharma to initiate Phase 1 clinical trial for IBA101 antibody - TipRanks
Liminatus Pharma’s IBA101 May Represent the CD47 Innovation Addressing Anemia and Thrombocytopenia in Advanced Immuno-Oncology - Bitget
Liminatus Pharma announces planned phase 1 clinical trial of IBA101, a next-generation CD47 blocking antibody - marketscreener.com
Liminatus Pharma Inc Stock (LIMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):